X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Aptar Pharma Bolsters Clinical Trial.

    Aptar Pharma Bolsters Clinical Trial Capabilities with Strategic Materials Manufacturing Acquisition

    FDA Accepts BLA for Recommended

    FDA Accepts BLA for Recommended Biosimilar to Simponi

    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Aptar Pharma Bolsters Clinical Trial.

    Aptar Pharma Bolsters Clinical Trial Capabilities with Strategic Materials Manufacturing Acquisition

    FDA Accepts BLA for Recommended

    FDA Accepts BLA for Recommended Biosimilar to Simponi

    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result

Cell Therapy Durability Response Summit 2022

Organised by Kisaco Research
August 22 - August 23, 2022
Hilton Boston Back Bay
Massachusetts - USA,

Hilton Boston Back Bay , Massachusetts, USA

The inaugural Cell Therapy Durability Response Summit is the only industry networking forum dedicated to the #1 challenge of the field: durability.

The summit will be held in Boston, Massachusetts from 22-23 August and there are over 23 speakers confirmed to give talks at the event. Speakers come from companies including Abbvie, Editas Medicine, Be Bipharma and many more! These talks will cover:

  • Target Selection and receptor design
  • Enhancing activity and persistence in the immunosuppressive tumor microenvironment
  • Genetic Engineering and synthetic biology
  • Moving beyond CAR-αβT and CAR-NK cells to generate durable responses

You can expect to meet researchers from cell therapy biotechs, representatives from pharmaceutical companies in the cell therapy space, academic experts and R&D solution providers, giving you the perfect chance to speak with experts in the industry.

Get the PDF agenda to find out more: https://hubs.ly/Q01dn9cL0

 

Event Date: 22-23 August 2022
Event Venue: Hilton Boston Back Bay, 40 Dalton St, Boston, MA 02115, United States
Event Organizers: Kisaco Research
Contact Number:+44 (0)20 3696 2920
Email: laura.hobson@kisacoresearch.com
Event Website: https://celltherapydurability.com

Enquiry

Latest

Aptar Pharma Bolsters Clinical Trial.
Clinical Trials

Aptar Pharma Bolsters Clinical Trial Capabilities with Strategic Materials Manufacturing Acquisition

24th July 2025
FDA Accepts BLA for Recommended
FDA Approvals

FDA Accepts BLA for Recommended Biosimilar to Simponi

22nd July 2025
Merck to Acquire Verona
Drug Development

Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

21st July 2025
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In